Your sex life after menopause: what changes, what can help
In this article
Sexual desire, comfort, arousal, and orgasm can change after menopause. Treatment options depend on which change bothers you. Low desire is not inevitable: interest can decrease, increase, or stay much the same. The Menopause Society’s sexual-health guidance.
You get to keep wanting a sex life that feels good. Start with what you would like to enjoy more.
Start with the part that changed
- Desire: You miss feeling interested in sex or thinking about it.
- Comfort: Dryness, irritation, or pain makes touch or penetration less enjoyable.
- Arousal: Your interest is there, but becoming physically or mentally excited feels different.
- Orgasm: Climax takes longer, feels different, or has become difficult to reach.
These concerns can overlap. Estrogen-related tissue changes can contribute to dryness and pain, while hot flashes and disrupted sleep can affect sexual interest. A clear assessment looks at the whole picture. The Menopause Society.
You do not need to use medical terminology. “I want sex, but it has started to hurt” gives a clinician a very different starting point from “Sex is comfortable, but I rarely feel interested.”
Comfort has its own treatment options
For vaginal dryness or discomfort, options include lubricants, vaginal moisturizers, and prescription treatments such as low-dose vaginal estrogen, vaginal DHEA, or ospemifene. Professional guidance matches treatment to symptom severity, health history, and patient preference. A history of breast cancer calls for individualized discussion with the oncology team. Menopause Society position statement on genitourinary symptoms.
To explore the formulations AnthologyRX offers, see estradiol vaginal cream and our estradiol safety guide. The current standalone 42.5 g option is FDA-approved generic estradiol vaginal cream 0.01% from Padagis, dispensed through GoGoMeds. The Pharmacy Hub preparation prescribed alongside Biest is separate and is not covered by that approval. Your prescription label identifies the preparation dispensed. Official label for the standalone cream.
Pain can also involve pelvic-floor or other conditions. Depending on the assessment, care may include pelvic-floor physical therapy or other treatment. ACOG sexual-health guidance.
Describe the kinds of touch you enjoy and the ones you avoid. That helps make the care relevant to your actual sex life.
Low desire deserves a conversation too
If reduced desire bothers you, an assessment can look at possible contributors and whether hypoactive sexual desire disorder, or HSDD, describes the concern. Clinical guidance includes medical, psychological, and relationship factors and supports individualized care, including sex therapy or other treatment when appropriate. ISSWSH process-of-care guideline.
There are several medication conversations worth knowing about:
Flibanserin, branded as Addyi: Its current U.S. indication includes women younger than 65 with acquired, generalized HSDD, including after menopause. It excludes low desire explained by another condition, relationship problems, or medication effects. It carries risks including low blood pressure, fainting, and sedation, with important alcohol and drug-interaction precautions. Current Addyi prescribing information.
Testosterone: ISSWSH guidance supports carefully monitored transdermal treatment for appropriately assessed postmenopausal women with HSDD. Long-term safety remains incompletely established, and testosterone is not FDA-approved for menopausal women. A testosterone level alone does not diagnose HSDD. ISSWSH guideline; FDA’s 2026 notice.
For a broader look at symptoms during the menopause transition and afterward, explore our hormone care options and comparison of estradiol patches, gel, and pills. Treatments for hot flashes or vaginal symptoms address different questions from medications considered for low desire.
Where does PT-141 fit after menopause?
Vyleesi, the FDA-approved bremelanotide product, is approved for acquired, generalized HSDD in premenopausal women. Its pivotal trials do not establish treatment benefit after menopause. Vyleesi prescribing information; RECONNECT publication.
Earlier research included postmenopausal women. FDA’s review describes an older nasal formulation study with response signals alongside nausea, vomiting, and blood-pressure concerns. It does not establish safety or effectiveness for today’s compounded injection after menopause. FDA multidisciplinary review, page 30.
AnthologyRX’s compounded PT-141 contains bremelanotide, the same active ingredient as Vyleesi. A licensed pharmacy prepares it for an individual prescription. It is a different, non-FDA-approved preparation; equivalent safety, effectiveness, and quality have not been established. Treatment information; FDA compounding information.
Bremelanotide can raise blood pressure and cause nausea; Vyleesi is contraindicated with uncontrolled hypertension or known cardiovascular disease. Review medication risks as part of the discussion. Prescribing information; PT-141 safety guide.
Make your appointment count
Bring three things: a description of what changed, a list of medications and relevant health history, and a goal that matters to you. Ask which concern the proposed treatment addresses, what improvement to look for, and when to reassess.
Your goal can be as simple as enjoying touch again or feeling interested more often. It does not need to match a partner’s expectations or your sex life at another age.
Questions people ask
Is low desire inevitable after menopause?
No. Experiences vary. If a change bothers you, you can ask for help; a particular frequency of sex is not a standard you must meet. The Menopause Society.
If sex hurts, should I try a libido medication first?
Describe the pain directly. An assessment can identify causes and options for comfort rather than assuming a desire treatment will resolve it. ACOG.
Does a low testosterone result tell me which treatment I need?
No. A lab result alone does not diagnose HSDD. Symptoms, context, and a clinical assessment guide the decision. ISSWSH guideline.
If bladder pain or urgency is also part of what has changed, our guide to interstitial cystitis and the BPC-157 research explains that separate assessment and why a specialized bladder study cannot establish a sexual-health benefit.
